Annotation Detail for AGAP2
Basic Information Top
| Gene Symbol: | AGAP2 ( CENTG1,FLJ16430,GGAP2,KIAA0167,PIKE ) |
|---|---|
| Gene Full Name: | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 |
| Band: | 12q14.1 |
| Quick Links | Entrez ID:116986; OMIM: 605476; Uniprot ID:AGAP2_HUMAN; ENSEMBL ID: ENSG00000135439; HGNC ID: 16921 |
| Relate to Another Database: | SFARIGene; denovo-db |
| No data |
| Pathway ID | Pathway Name |
|---|---|
| hsa04144 | Endocytosis |
| Pathway ID | Pathway Name |
|---|---|
| Axon guidance |
| Pathway ID | Pathway Name |
|---|---|
| 200183 | Trk receptor signaling mediated by PI3K and PLC-gamma |
| 200074 | Netrin-mediated signaling |
| No data |
| Pathway ID | Pathway Name |
|---|---|
| 500088 | Netrin-1 signaling |
| No data |
| No data |
| No data |
| No data |
| No data |
| Chemical ID | Chemical Name | Interaction | Interaction Action | Publication |
|---|---|---|---|---|
| D000643 | Ammonium Chloride | Ammonium Chloride affects the expression of AGAP2 mRNA | affects expression | 16483693 |
| C055494 | caffeic acid phenethyl ester | [Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AGAP2 mRNA | affects cotreatment|decreases expression | 20360939 |
| D004052 | Diethylnitrosamine | [Diethylnitrosamine co-treated with caffeic acid phenethyl ester] results in decreased expression of AGAP2 mRNA | affects cotreatment|decreases expression | 20360939 |
| D018038 | Sodium Selenite | Sodium Selenite results in increased expression of AGAP2 mRNA | increases expression | 18175754 |
| Disease ID | Disease Name | Direct Evidence | Inference Chemical Name | Inference Score | Publication |
|---|---|---|---|---|---|
| MESH:D000138 | Acidosis | Ammonium Chloride | 4.19 | 18287403 | |
| MESH:D000236 | Adenoma | Diethylnitrosamine | 3.05 | 10737359 6695378 | |
| MESH:D018248 | Adenoma, Liver Cell | Diethylnitrosamine | 4.53 | 17162532 19052882 18056438 17620307 16434500 19061943 | |
| MESH:D001943 | Breast Neoplasms | Diethylnitrosamine | 2.19 | 17474063 | |
| MESH:D006528 | Carcinoma, Hepatocellular | Diethylnitrosamine | 1.88 | 18393292 17173139 16569478 16698587 19052882 18506893 18210153 19539802 18788625 17428255 3084413 20935162 16935385 19335982 20514400 18785209 20214788 17138121 16502159 19822196 16328049 19701751 17761372 16807293 16878318 19171122 20727157 3581430 18056438 20007298 17055752 20084675 18971187 19519916 10737359 21159647 18494052 19394651 10672840 16288022 19919837 16779866 20512989 11831363 19107877 16540662 19208518 17978847 18691550 16830150 19418558 20524982 17162532 20101231 18978308 16681979 18665156 20432363 19383236 | |
| MESH:D002471 | Cell Transformation, Neoplastic | Diethylnitrosamine | 3.12 | 21159647 7505956 17174075 2727394 | |
| MESH:D018281 | Cholangiocarcinoma | Diethylnitrosamine | 4.05 | 19052882 | |
| MESH:D019457 | Chromosome Breakage | Sodium Selenite | 5.31 | 15894690 | |
| MESH:D003920 | Diabetes Mellitus | Sodium Selenite | 4.15 | 16285004 | |
| MESH:D003924 | Diabetes Mellitus, Type 2 | Diethylnitrosamine | 2.26 | 20387270 | |
| MESH:D056486 | Drug-Induced Liver Injury | Diethylnitrosamine | 4.31 | 19107877 | |
| MESH:D056486 | Drug-Induced Liver Injury | Sodium Selenite | 4.31 | 15131321 | |
| MESH:D004931 | Esophageal Achalasia | Diethylnitrosamine | 5.84 | 16302075 | |
| MESH:D005234 | Fatty Liver | Diethylnitrosamine | 3.61 | 20387270 21071580 | |
| MESH:D007249 | Inflammation | Diethylnitrosamine | 2.55 | 18785209 | |
| MESH:D007333 | Insulin Resistance | Sodium Selenite | 3.52 | 14714311 | |
| MESH:D007414 | Intestinal Neoplasms | caffeic acid phenethyl ester | 4.98 | 10783313 | |
| MESH:D007674 | Kidney Diseases | caffeic acid phenethyl ester | 3.75 | 15369732 | |
| MESH:D015473 | Leukemia, Promyelocytic, Acute | caffeic acid phenethyl ester | 4.23 | 16766008 | |
| MESH:D008103 | Liver Cirrhosis | Diethylnitrosamine | 3.01 | 18522880 19638242 18665156 20032147 18407596 | |
| MESH:D008107 | Liver Diseases | Diethylnitrosamine | 2.17 | 17034775 | |
| MESH:D008113 | Liver Neoplasms | Diethylnitrosamine | 2.35 | 2862719 21047994 2422723 20405173 20101389 20492335 19850985 12771043 19551842 19256749 18648771 19073162 15885732 19638242 20434301 20137499 21071580 19499222 19642983 19690152 19090486 12112319 20501860 19255062 18978307 19996281 20118626 19426721 19254457 19833225 15175105 9163691 21167192 16942905 20452335 20583210 18754104 10737359 18977376 19427195 18644402 21278145 19294768 19812893 | |
| MESH:D008114 | Liver Neoplasms, Experimental | Diethylnitrosamine | 2.85 | 19126423 18079962 18253720 16267830 3124819 18775883 17942915 18544905 18164116 19539802 18093689 19009564 19519916 19004024 18308698 17174075 2563599 9362446 17854601 21159647 18282651 16842330 | |
| MESH:D008175 | Lung Neoplasms | Diethylnitrosamine | 1.77 | 20970405 6695378 21163286 20512841 | |
| MESH:D016393 | Lymphoma, B-Cell | Sodium Selenite | 4.52 | 14737004 | |
| MESH:D009362 | Neoplasm Metastasis | Diethylnitrosamine | 2.69 | 3581430 9029167 | |
| MESH:D019636 | Neurodegenerative Diseases | Diethylnitrosamine | 3.69 | 20387270 | |
| MESH:D009461 | Neurologic Manifestations | Diethylnitrosamine | 5.84 | 20387270 | |
| MESH:D010190 | Pancreatic Neoplasms | Diethylnitrosamine | 2.53 | 16540662 | |
| MESH:D011230 | Precancerous Conditions | Diethylnitrosamine | 3.92 | 2563599 | |
| MESH:D011471 | Prostatic Neoplasms | Sodium Selenite | 3.33 | 18760546 | |
| MESH:D013274 | Stomach Neoplasms | Diethylnitrosamine | 1.76 | 18456281 | |
| MESH:D013964 | Thyroid Neoplasms | Diethylnitrosamine | 3.29 | 7505956 |
| Pathway ID | Pathway Name |
|---|---|
| REACT:18266 | Axon guidance |
| KEGG:04144 | Endocytosis |
Drug Bank